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SUMMARY
A murine monoclonal antibody (mAb), 3F10, was produced by fusion of spleen cells obtained from
mice immunized with a rat cortical thymic epithelial cell line (R-TNC.1) stimulated with interferon-
c and P3X myeloma cells. 3F10 recognized an antigen expressed both on thymocytes and non-
lymphoid cells in the thymus. Flow cytometry showed that 3F10 stained more than 98% thymocytes
and 90% R-TNC.1 cells. Immunoprecipitation and Western blot studies demonstrated that 3F10
reacted with molecules of 55 000 and 65 000 MW from both thymocyte and R-TNC.1 cell lysates.
3F10 recognized the same antigen on Chinese hamster ovary cells transfected with rat Crry as did
5I2 mAb, confirming the specificity of 3F10 mAb for the rat homologue of mouse Crry/p65, a
membrane-bound complement regulatory protein. 3F10 mAb induced homotypic aggregation of
thymocytes and exhibited an additive effect on the aggregation evoked by phorbol myristate
acetate. The aggregation was dependent on active cell metabolism, intact cytoskeleton, divalent
cations and activation of protein phosphatases 1 and 2A (as assessed by use of okadaic acid). In
contrast, H-7, HA1004 and genistein partially inhibited, whereas staurosporine potentiated the
aggregation of thymocytes triggered by 3F10. 3F10 mAb also stimulated binding of thymocytes to
the R-TNC.1 line. Both homotypic and heterotypic adhesive interactions are mediated by leucocyte
function-associated antigen-1 (LFA-1). In addition, 3F10 stimulated proliferation of thymocytes
induced by suboptimal concentrations of concanavalin A. These data suggest that rat Crry/p65
might be involved in the regulation of both cell adhesion and activation of thymocytes. This is a
novel, non-complement-dependent function of Crry/p65.
INTRODUCTION
The thymus has an important role in the generation of T cells.
It provides a microenvironment for a complex series of steps in
intrathymic T-cell development: the attraction of precursors,
commitment to the T-cell lineage, induction of the T-cell
receptor gene rearrangement, accessory molecule expression,
repertoire expansion, major histocompatibility complex
(MHC) molecule-based selection (positive and negative),
acquisition of functional maturity and migratory capacity.1
This maturation process involves bidirectional interactions
between developmental thymocytes and different components
of the thymic microenvironment, such as epithelial cells,
dendritic cells, macrophages, fibrous stroma, and extracellular
matrix.2,3 Interactions involve direct cell–cell contacts and
soluble mediators (cytokines, thymic hormones and other
biologically active substances). Numerous studies suggested
that direct contacts between thymic epithelial cells (TEC) and
developing thymocytes are mediated by specific cell-surface
interactions such as CD2/leucocyte function-associated antigen
(LFA)-3, LFA-1/intracellular adhesion molecule (ICAM)-1,
class I MHC/CD8, class II MHC/CD4, Thy-1, very late antigen
(VLA)-4 and several newly discovered adhesion molecule
(reviewed in 4).
A recent approach to the analysis of these intrathymic
mechanisms has been to raise monoclonal antibodies (mAb)
to molecules expressed by TEC.5 Unexpectedly, some of the
mAb raised against TEC recognize antigenic determinants
shared between TEC and developing thymocytes.6–10 Detailed
studies have confirmed that usually both cell types synthesize
the molecules de novo and that the antigen detected on the
two populations is genuinely the same, rather than simply
sharing a cross-reactive epitope.6,7,9 The significance of
molecules shared between two interacting cells in the thymus
is not clear. They could be involved in homotypic and
heterotypic binding with the same or a complementary
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structure on the opposing cell surface, respectively, or serve as
receptors for soluble ligands.2,3
We have recently produced a mAb, named 3F10, which
recognizes one such shared antigen expressed both on
thymocytes and non-lymphoid cells in the rat thymus. We
report here that it is specific for the rat Crry/p65 antigen, a
complement regulatory membrane protein. The mAb stimu-
lates homotypic aggregation of thymocytes and proliferation of
these cells to suboptimal concentrations of concanavalin A
(Con A). In addition, it increases heterotypic binding of
thymocytes to a rat TEC line in vitro. Both adhesive
interactions are LFA-1 dependent. This is a novel role of rat
Crry/p65, not recognized so far.
MATERIALS AND METHODS
Monoclonal antibodies and reagents
3F10 mAb was produced at the Institute of Medical Research
(MMA), Belgrade, Yugoslavia. Briefly, fusion was performed
between P3X myeloma cells and splenocytes from mice
immunized with a rat cortical TEC line (R-TNC.1) stimulated
with interferon-c (IFN-c). This mAb (immunoglobulin G1,
IgG1) was purified by salt fractionation. Biotinylation of the
mAb was performed using N-hydroxysuccinimido (NHS)-
biotin (Sigma, St Louis, MO). 5I2 mAb (IgG1) reactive with
the rat Crry molecule was produced at the Department of
Molecular Biology, Nagoya City University School of
Medicine, Nagoya, Japan by Takizawa et al.11 WT.3 (anti-
rat CD18; IgG1), WT.1 (anti-rat CD11a; IgG2a) and 1A29
(anti-rat CD54; IgG1) were produced at the Department of
Immunology, Metropolitan Institute of Medical Science,
Tokyo, Japan12 and were kindly donated by Prof. M.
Miyasaka, Osaka, Japan. R73 (anti-rat ab T-cell receptor,
TCR) and W3/25 (anti-rat CD4) mAb were purchased from
Serotec, Oxford, UK. A peroxidase-conjugated rabbit anti-
mouse immunoglobulin was purchased from Dako, Denmark,
whereas a sample of fluoroscein isothiocyanate (FITC)-
conjugated sheep anti-mouse immunoglobulin was obtained
from Inep, Zemun, Yugoslavia.
The reagents used were: phorbol myristate acetate (PMA;
Sigma), sodium azide (Merck, Darmstadt, FRG), cytochalasin
B (Sigma), cycloheximide (Sigma), 1-(5-isoquinolinylsulpho-
nyl)-3-methyl-piperazine (H-7; Sigma), N-(6-aminohexyl)-
1-naphthalenesulphonamide (W-7; Sigma), N-(2-guanidi-
noethyl)-5-isoquinolinesulphonamide (HA1004; Sigma), genis-
tein (ICN, Clevelend, OH), okadaic acid (Sigma), wortmannin
(Sigma), staurosporine (Sigma), bisindolylmaleimide (Calbio-
chem, San Diego, CA), Con A (Sigma)
Cells and cell lines
AO rats, male, 6–8-week-old, bred at the Farm for Experi-
mental Animals, MMA (Belgrade, Yugoslavia), were used as a
source of thymocytes. Thymocytes were isolated from thy-
muses by teasing the organs against a stell mesh to obtain a
single-cell suspension. The R-TNC.1 line was established at the
Institute of Medical Research, MMA (Belgrade, Yugoslavia).
This line was characterized as a type of rat cortical TEC with
the nursing activity.13 It was propagated in RPMI-1640
medium (Serva, Heidelberg, Germany) containing 15% fetal
calf serum (FCS; Flow Laboratories, Irvine, UK), 5 mg/ml
insulin (Serva), 50 nm dexamethasone (ICN-Galenika,
Belgrade, Yugoslavia) and 10 ng/ml epidermal growth factor
(EGF; Serva). The coding region for the rat 5I2 antigen was
from the cDNA plasmid clone 18.14 The 5I2 antigen cDNA was
subcloned into SalI and SpeI sites (sense strand vector) or SacI
and KpnI sites (antisense strand vector) of the eukaryotic
expression vector pBK-cytomegalovirus (CMV) (Stratagene,
La Jolla, CA). The sense strand vector was removed from the
NheI to SpeI region (the region containing the lac promoter
and lacZ ATG). Both vectors were digested by NaeI to
linearalize before transfection. The Chinese hamster ovary
(CHO) cell line was transfected by electroporation using Gene
Pulser (Bio-Rad Laboratories, Hercules, CA).
Flow cytometry
Thymocytes (1r106/tube) and R-TNC.1 cells (2r105/tube)
were incubated with 5 mg/ml 3F10 mAb in phosphate-buffered
saline (PBS) containing 0.1% sodium azide and 2% FCS (PBS/
FCS) for 30 min at 4u, washed twice with PBS/FCS, and
stained with FITC-conjugated goat anti-mouse IgG for 30 min
at 4u. Double immunofluorescence was used to determine the
expression of 3F10 on different thymocyte subsets. For this
purpose thymocytes were incubated with saturating concentra-
tions of mAbs at the following order: R73 mAb, anti-mouse
immunoglobulin FITC, 3F10 biotinylated antibody, strepta-
vidin–phycoerythrin (PE). After the final washing with PBS/
FCS and PBS, respectively, cells were analysed on an EPICS
XL-MLC cytofluorometer (Coulter, Krefeld, Germany) using
single- or double-colour immunofluorescence. In the experi-
ments using double staining the expression of 3F10 was
determined on ab TCR–, ab TCRlo and ab TCRhi thymocyte
subsets. 5I2 antigen sense strand cDNA transfected or control
(antisense strand transfected) CHO cells were suspended by
incubating with 0.02% ethylenediamine tetra-acetic acid
(EDTA)/PBS for 10 min at 37u. Cell suspensions containing
1r106 cells were incubated with 10 mg/ml goat IgG (Chemi-
con, Temecula, CA) for 10 min at room temperature to block
non-specific binding. Then 3F10 mAb or 5I2 mAb were added
to cells at final concentration 20 mg/ml and incubated for
30 min on ice. The suspensions were centrifuged and washed
three times with cold PBS, followed by incubation with FITC-
conjugated goat anti-mouse immunoglobulin (Becton Dick-
inson, Mountain View, CA) for 30 min on ice and washed.
Finally, cells were analysed by fluorescence-activated cell
sorting on a FACSCulibur (Becton Dickinson). Dead cells
were excluded using staining with 2 mg/ml propidium iodide.
Immunoperoxidase staining
Cryostat sections of rat thymuses were fixed in acetone for
10 min, air dried and washed in Tris-buffered saline (TBS). The
fixed sections were incubated for 30 min in methanol contain-
ing 0.3% H2O2 for inhibition of endogenous peroxidase
activity. After washing in TBS, the sections were incubated
with 3F10 mAb for 30 min, washed, and incubated 30 min
with goat anti-mouse IgG conjugated with peroxidase (Dako).
Revelation of the peroxidase activity was demonstrated by
0.06% diaminobenzidine (DAB; Serva) and 0.01% H2O2. After
washing, the sections were counterstained with haematoxylin
prior to mounting, and were observed under a conventional
light microscope.
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Western blotting
Trypsinized R-TNC.1 cells (0.1% trypsin in 0.02% EDTA) and
thymocytes were washed three times in PBS. Cells (3r108
thymocytes or 1r107 R-TNC.1 cells) were lysed in 1 ml ice-
cold lysis buffer containing 0.5% Nonidet P-40, 50 mM Tris
(pH 7.6), 300 mM NaCl, and 10 mg/ml of aprotinin, iodoace-
tamide, leupeptin and phenylmethylsulphonyl fluoride for
15 min on ice, centrifuged at 12000 g for 10 min, and soluble
materials were diluted 1 : 1 with sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) sample
buffer without 2-mercaptoethanol (2-ME). For Western
blotting, the cell lysates were boiled for 3 min and run on
10% SDS–PAGE (30 ml per lane) transferred to polyvinylidene
difluoride (PVDF) membranes and blotted with 3F10 mAb
followed by a peroxidase-conjugated secondary antibody.
Proteins were visualized by 0.5% DAB and 0.01% H2O2. A
mixture of standard protein markers (Sigma) was used for the
determination of relative molecular mass.
Immunoprecipitation
Thymocytes (3r107/ml) in cold RPMI-1640 medium (pH 8.0)
were incubated 40 min at 4u with 0.2 mg/ml normal human
serum (NHS)–biotin, washed three times in RPMI-
1640 pH 7.2–7.4, and lysed in 300 ml lysis buffer as described
above. Biotinylated thymocyte lysate was incubated overnight
at 4u with the indicated mAb adsorbed to protein A–sepharose.
To avoid non-specific adsorption, lysates were precleared for
2 hr with protein A–sepharose. Immunoprecipitates were
centrifuged at 12 000 g for 2 min, washed three times in lysis
buffer containing 0.1% Nonidet P-40, resuspended in 80 ml
SDS–PAGE sample buffer without 2-ME and resolved by
electrophoresis on 10% PAGE. Immunoblot analysis was
performed by transferring separated proteins onto the PVDF
membrane. The membrane was then probed with 1 : 800
dilution of peroxidase-conjugated streptavidin. In experiments
in which the relationship between 3F10 and 5I2 antigen
was studied, lysates of nonlabeled thymocytes were immuno-
precipitated with 3F10 mAb, run on 10% PAGE, transferred
onto PVDF membrane and then analysed by Western blotting
with either 3F10 or 5I2 mAb.
Semiquantitative aggregation assay
To measure homotypic adhesion we used the modified method
described by Rothlein and Springer.15 Thymocytes were
resuspended in RPMI-1640 medium with 10% FCS at 5r106
cells/ml and placed in 96-well flat-bottom microtitre plates
(ICN, Costa Mesa, CA). The cells were incubated at 37u in the
absence or presence of mAbs and/or PMA. Inhibition
experiments were done by preincubating cells with the
indicated blocking mAb at 4u or with different reagents at
37u for 30 min. The plates were observed by indirect
microscopy after various time periods. Scores ranged from 0
to 5: 0, no aggregation; 1, less than 10% of the cells in
aggregates; 2, 10–50% of the cells formed small clusters; 3, 50–
80% of the cells in small loose and/or compact clusters; 4,
>80% of the cells formed large loose and/or compact clusters;
5, nearly 100% of the cells in large very compact aggregates.
Results were scored by two independent observers.
Quantitative aggregation assay
Thymocytes were resuspended in RPMI-1640 with 10% FCS at
1r107/ml and placed in 2-ml plastic tubes. Stimuli were added
in a final volume of 200 ml/tube and cells were incubated at 37u
for 2 hr. Where indicated, cells were preincubated with the
various mAbs at 4u or metabolic inhibitors at 37u for 30 min.
After incubation cells were mildly vortexed and free cells were
counted:
% cells in aggregates = 100 r[1 x (number of free cells after
incubation)/(number of free cells in control before incubation)].
Figure 1. Immunoperoxidase staining of the rat thymus by 3F10 mAb (a) and secondary antibody alone (negative control) (b). 3F10
antigen is expressed on both thymocytes and stromal cells. Original magnifications: r16.
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Controls were cells incubated in the same conditions but
without stimuli.
Binding assay
Trypsinized R-TNC.1 cells were plated on 96-well flat-
bottomed plates (Flow laboratories; 1r104 cells/well in
200 ml of medium) and grown for 2 days until confluent
monolayers were obtained. For experiments, the enriched
medium used for standard growth of these cells was replaced
with RPMI-1640 medium containing 10% FCS. Resting adult
thymocytes (5r105 cells/well) were added to the wells and spun
on confluent monolayers (20 g, 1 min). After 45 min of
incubation at 37u, the plates were spun upside down (100 g,
30 s) and quickly filled with medium to prevent drying and
subsequent damage of cells. Thymocytes were detached from
Figure 2. Surface expression of the 3F10 antigen on thymocytes (a) and R-TNC.1 cells (b). Cells in suspension were incubated with
3F10 biotinylated mAb followed by staining with PE (thymocytes) or 3F10 unconjugated mAb and then with FITC-conjugated goat
anti-mouse IgG (R-TNC.1 cells) and than analysed on an EPICS XL-MCL cytofluorometer. Percentages of positive cells and MF
intensities given on histograms were subtracted from negative controls (hatched areas). Expression of the 3F10 antigen on thymocyte
subsets according to the expression of ab TCR. Cells were labelled with R73 and 3F10 mAb as described and processed for double
immunofluorescence analysis. The histograms for the 3F10 antigen expression on ab TCR– (d), ab TCRlo (e) and ab TCRhi (f)
thymocyte subsets were determined according to the different staining of thymocytes by R73 mAb (c).
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monolayers by pipetting. The antibody-mediating modulation
of cell binding was assayed by preincubating thymocytes or R-
TNC.1 cells with mAb for 30 min at 4u. All antibodies were
continuously present during the assay. The number of attached
cells was then counted and percentage binding was calculated
as follows:
% binding = number of attached thymocytes/number of total
thymocytes r 100
The percentage of relative binding in the presence of specific
or irrelevant mAb was calculated by comparing to correspond-
ing controls (cells without mAb).
Proliferation assay
Thymocytes were cultivated in 96-well plates (1r106/well) in
the presence of 2.5 mg/ml or 0.625 mg/ml Con A without or
with the addition of different concentrations of soluble
3F10 mAb or irrelevant mAb (IrmAb) (reactive with Blas-
tocystis hominis, IgG1). Cells were cultured for 3 days, and
[3H]thymidine was added during the last 18 hr of culture.
Incorporated [3H]thymidine was measured as c.p.m. using a
liquid scintillation counter (Beckman). Each test was done in
triplicate.
RESULTS
Expression of the antigen recognized by 3F10 mAb in the
thymus
3F10 mAb (IgG1) was recently established at the Institute of
Medical Research, MMA, Belgrade, by fusing P3X myeloma
cells and splenocytes from mice immunized with a rat cortical
TEC line (R-TNC.1) stimulated with IFN-c. The first aim of
this study was to investigate binding of the 3F10 mAb on
cryostat sections of the rat thymus using an immunoperoxidase
method. Figure 1 demonstrates that both thymocytes and non-
lymphoid cells, including TEC, throughout the thymus were
strongly positive. Flow cytometry showed membranous
expression of the antigen by more than 98% thymocytes and
more than 89% R-TNC.1 cells (Fig. 2). Double immunofluor-
escence demonstrated that all thymocyte subsets (ab TCR–, ab
TCRlo and ab TCRhi) expressed the 3F10 antigen (Ag).
However, based on the mean fluorescence (MF) intensity its
expression on the ab TCRhi thymocyte subset was higher
compared to total thymocytes or other two cell subsets (Fig. 2).
Biochemical characterization of the 3F10 antigen
In order to define biochemical characteristics of the antigen
recognized by 3F10, we analysed the lysates of thymocytes and
R-TNC.1 cells by Western blotting and immunoprecipitation.
Western blotting of both thymocyte and R-TNC.1 cell lysates
using 3F10 mAb results in a dual band of 65 000 MW and
55 000 MW under non-reducing conditions (Fig. 3a). Under
reducing conditions, 3F10 mAb did not react with the target
molecules on the PVDF membrane (data not shown).
Immunoprecipitation study of the thymocyte lysate also
showed that 3F10 mAb immunoprecipitated molecules of
approximately 65 000 and 55 000 MW (Fig. 3b). Recently, it
has been demonstrated that a murine mAb, 5I2, specific for the
rat homologue of the mouse Crry/p65 (a regulator of
complement activation) immunoprecipitated a molecular
complex from the rat erythrocyte lysate of the same
biochemical characteristics as 3F10 mAb.11 We showed that
5I2 mAb also recognized the 65/55 heterodimer in Western blot
of the thymocyte lysate (Fig. 3a). In order to clarify whether
these mAbs recognize the same antigens, the thymocyte lysate
was immunoprecipitated with 3F10 mAb, resolved on 10%
PAGE, transferred onto the nitrocellulose membrane and
stained with 3F10 and 5I2 mAb. Results presented in Fig. 3(c)
Figure 3. (a) Western blot of 3F10 antigen and 5I2 antigen from thymocyte and R-TNC.1 lysates. Lysates were resolved on 10%
PAGE under non-reducing conditions, transferred to PVDF membrane, and blotted with 3F10 or 5I2 mAb (lane 1:
thymocytesx3F10, lane 2: thymocytesx5I2, lane 3: thymocytes–negative control, lane 4: R-TNC.1–3F10, lane 5: R-TNC.1–
negative control). (b) Immunoprecipitation of 3F10 antigen from the rat thymocyte lysate. Thymocytes were surface biotinylated,
lysed in 0.5% NP-40 and soluble material was immunoprecipitated with 3F10 mAb (lane1), positive control, anti-CD4 mAb (lane 2)
or control IgG (lane 3), resolved on 10% PAGE under non-reducing conditions, transferred, and blotted with streptavidin–peroxidase.
(c) Comparison of 3F10 and 5I2 mAb reactivity. Thymocyte lysate was immunoprecipitated with 3F10 mAb, resolved on 10% PAGE
under non-reducing conditions, transferred to PVDF membrane, and analysed with 3F10 mAb (lane 1), 5I2 mAb (lane 2) or with
secondary antibody alone (lane3). Note the same reactivity of both mAb with the 65/55 000 MW heterodimer.
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clearly demonstrate that 5I2 and 3F10 showed the same
specificity.
3F10 mAb binds to CHO cells transfected with the rat
Crry/p65
The final evidence for the specificity of 3F10 was obtained by
testing its reactivity with the rat Crry-transfected CHO cells by
flow cytometry. As shown in Fig. 4, both 3F10 and 5I2 mAb
equally stained CHO-transfected, but not control CHO cells,
confirming again the specificity of 3F10 mAb for the rat Crry/
p65 antigen.
3F10 promotes homotypic adhesion of rat thymocytes
Initial experiments showed that 3F10 mAb was able to induce
homotypic aggregation of rat thymocytes. Relatively weak, but
still visible, aggregation was also observed using 5I2 mAb (data
not shown). To explore this phenomenon in more detail, we
compared thymocyte aggregation induced by 3F10 and PMA.
Results presented in Fig. 5 show that 3F10 induced moderate
homotypic aggregation of thymocytes (maximum score aggre-
gation 2 after 2 hr). Similar or a bit stronger aggregation was
observed using PMA whereas both agents had additive effects.
Thymocyte aggregation was optimal using 25 mg/ml 3F10 and
was still visible at the concentration as low as 0.5 mg/ml (data
not shown).
Requirements for the 3F10-induced homotypic adhesion
The next experiments were designed to study the physiologic
requirements for the 3F10-induced homotypic aggregation.
The results are presented in Table 1. 3F10 did not induce
aggregation of thymocytes in HBSS medium without divalent
cations (Ca2+ and Mg2+) or with Ca2+ only, while the
aggregation was restored in HBSS with Mg2+ in a dose-
dependent manner. Similarly, the PMA-evoked aggregation
required only Mg2+, but neither Mg2+ concentrations used (1–
5 mM) did not restore adhesion to the level seen in complete
medium containing 10% FCS. Addition of Ca2+ in Hank’s
balanced salt solution (HBSS) with Mg2+ significantly
increased both PMA and 3F10-evoked aggregation. The
3F10-induced aggregation was fully prevented by incubating
cells at 4u or in the presence of sodium azide, confirming its
dependence upon active cell metabolism and actin cytoskeleton
(Table 1). Cycloheximide, an inhibitor of protein synthesis,
had no effect on the aggregation. To determine the intracellular
signalling pathways involved in the 3F10-induced aggregation,
we preincubated thymocytes with different concentrations of
H-7 (an inhibitor of protein kinase A (PKA), PKC and PKG),
HA1004 (an inhibitor of PKA and PKG), staurosporine (a
non-selective PK inhibitor), bisindolylmaleimide (a specific
PKC inhibitor), genistein (an inhibitor of protein tyrosine
kinases), okadaic acid (an inhibitor of protein phosphatases
(PP)1 and 2A), W-7 (a blocker of calmodulin-dependent
protein kinase) and wortmannin (an inhibitor of phosphati-
dylinositol 3-kinase). Table 1 shows that homotypic adhesion
of thymocytes triggered by 3F10 mAb was partially suppressed
by H-7, HA1004 and genistein and completely inhibited by
okadaic acid. The adhesion was not modified by using
bisindolylmaleimide, W-7 and wortmannin. Staurosporine
potentiated the 3F10-induced homotypic aggregation of
Figure 4. Reactivity of 3F10 and 5I2 mAb with rat Crry transfected CHO cells. CHO cells transfected with rat Crry as well as control
CHO cells were incubated with 3F10 or 5I2 mAb followed by FITC-conjugated goat anti-mouse immunoglobulin. Cells were than
analysed using FACSCulibur (Becton Dickinson). Note that both mAb stain Crry-transfected, but not control CHO cells. Hatched
areas represent corresponding negative controls.
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thymocytes. These results indicate that activation of PKC and/
or PKA/PKG, PP1 and/or 2A and tyrosine kinases is an
important event for the 3F10-induced aggregation of thymo-
cytes. The effects of metabolic inhibitors, which modulate the
3F10-induced aggregation of thymocytes observed semiquan-
titatively in microtitre plates, were also confirmed using a
quantitative method (Table 1).
3F10 induces homotypic adhesion of thymocytes through an
LFA-1-dependent/ICAM-1-independent pathway
Previous results suggest that signalling requirements for the
3F10-induced aggregation of thymocytes are similar with those
mediated by b2 integrins. To prove this hypothesis, we
preincubated thymocytes with anti-CD11a (WT.1), anti-
CD18 (WT.3) and anti-CD54 (1A29) mAb, and then
stimulated with 3F10. Aggregation was measured quantita-
tively or semiquantitatively. As demonstrated in Fig. 6(a), the
3F10-induced aggregation was completely blocked by WT.3
and significantly inhibited by WT.1 mAb. In contrast,
1A29 mAb only slightly inhibited the aggregation. These
results suggest that homotypic aggregation of thymocytes
evoked by 3F10 is LFA-1 dependent/partly ICAM-1 depen-
dent.
3F10 mAb potentiates thymocyte adhesion to the R-TNC.1
line
We have previously demonstrated that the R-TNC.1 cell line is
a type of rat cortical TEC with nursing activity which was
manifested by the binding and subsequent engulfment of
thymocytes.13 In this work, we studied the effect of 3F10 mAb
on thymocyte binding to the R-TNC.1 line. As can be seen in
Fig. 6(b) 3F10 also stimulated heterotypic adhesion of
thymocytes to the R-TNC.1 line (stimulation was approxi-
mately 50%). Stimulatory effect of 3F10 mAb on thymocyte
binding to R-TNC.1 cells was not simply a consequence of
cross-linking these cells by mAb because preincubation of both
thymocytes and the TEC line with saturation concentrations of
3F10 mAb also increased cell adhesion (data not shown). In
order to determine whether this process is also mediated by b2
integrins, we pretreated thymocytes with anti-LFA-1 or anti-
CD18 mAb and R-TNC.1 cells with anti-ICAM-1 mAb for
30 min prior to the binding assay. Figure 6(b) shows that mAb
to LFA-1 and CD18 partly suppressed thymocyte binding to
R-TNC.1 cells, whereas anti-ICAM-1 mAb did not signifi-
cantly modulate the adhesion process.
3F10 mAb stimulates proliferation of thymocytes triggered by
Con A
Finally, we tested whether 3F10 modulates both spontaneous
and Con A-induced proliferation of thymocytes. Results
presented in Fig. 7 show that the mAb (at concentrations
between 2.5 mg/ml and 25 mg/ml) significantly stimulated
proliferation of thymocytes triggered by the suboptimal Con
A concentration (0.625 mg/ml). Maximal proliferation was seen
using 5 mg/ml of 3F10 mAb. 3F10 mAb did not significantly
Figure 5. Induction of the thymocyte aggregation by 3F10, PMA or their combination. (1) Medium; (2) 3F10 mAb; (3) PMA; (4)
PMA+3F10 mAb. Cells were plated in 96-well plates (at 1r106/well) with addition of 3F10 (25 mg/ml), PMA (50 ng/ml) or their
combinations, incubated at 37u and photographed after 2 hr of culture. Original magnification: r25.
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modulate either spontaneous thymocyte proliferation or
proliferation of these cells evoked by the optimal ConA
concentration (2.5 mg/ml) (not shown).
DISCUSSION
The aim of the work presented in this paper was to explore the
nature and function of the molecule detected by 3F10 mAb.
This mAb was raised against rat cortical TEC line (R-TNC.1)
previously established at the Institute of Medical Research,
MMA, Belgrade.13 Immunohistochemistry and flow cytometry
demonstrated that 3F10 mAb binds to both of thymocytes and
thymic non-lymphoid cells, including the R-TNC.1 line. By
these criteria, the 3F10 antigen belongs to a family of thymic
shared molecules.2,3 Because the antigen is expressed on all
TEC 3F10 mAb belongs to the group I of clusters of thymic
epithelium staining (CTES) nomenclature.3
Immunoprecipitation experiments showed that 3F10 anti-
gen is expressed in two forms with molecular masses of 65 and
55 000 MW. The two bands are identical in lysates from both
thymocytes and the R-TNC.1 cell line. Because the molecules
are detected by Western blotting, it can be postulated that each
polypeptide carries the 3F10 epitope.
Based on cell distribution and biochemical characteristics
of the 3F10 antigen, we proposed that the molecule might be
the rat counterpart of mouse Crry/p65, a cell surface
glycoprotein that belongs to the group of membrane-bound
complement regulatory molecules.16,17 In humans, decay-
accelerating factor (DAF, CD55), membrane cofactor protein
(MCP, CD46), C8 binding protein (C8bp, homologous
restriction factor of 60 000 MW, HRF), homologous restric-
tion factor 20 (HRF20, CD59) and complement receptor 1
(CR1, CD35) have been reported as membrane-associated
proteins which regulate complement activation.18–20 One of the
rat complement regulatory factors has been identified by
5I2 mAb.11 Cloning experiments showed that the molecule
possesses the same structure as mouse Crry/p65,14 which
functions like DAF and/or MCP in humans.21 To confirm this
hypothesis, we have compared the reactivity of 3F10 and
5I2 mAbs in Western blots of thymocyte lysates and with CHO
Table 1.0Requirements for 3F10- and PMA-induced aggregation of
thymocytes
Aggregation
Semiquantitative
Chemical/condition
3F10
(score)
PMA
(score)
Quantitative
3F10 (%)
Medium 2 3 39.99t4.60
EDTA 0 0 NT
Mg2+Ca2+-free HBSS 0 0 NT
Mg2x (1 mM) 1 0 NT
Mg2+ (2.5 mM 2 01.5 NT
Mg2+ (5 mM) 03.5 1 NT
Mg2+ (1 mM)+Ca2+ (5 mM) 03.5 02.5 NT
Mg2+ (5 mM)+Ca2+ (5 mM) 03.5 03.5 NT
Sodium azide (0.2%) 0 0 NT
Cytohalasin B (5 mg/ml) 0 0 NT
Cycloheximide (10 mg/ml) 2 3 NT
H-7 (80 mM) 1 3 25.63t2.04*
HA 1004 (5 mM) 1 3 26.75t7.30*
Genistein (50 mg/ml) 1 3 27.70t8.70*
Okadaic acid (1 mM) 0 0 11.96t2.58*
Bisindolylmaleimide (1 mM) 2 00.5 NT
Wortmannin (5 nM) 2 3 NT
W-7 (20 mM) 2 3 NT
Staurosporine (0.5 mM) 4 00.5 68.76t1.85*
Thymocytes were cultured in the presence of 3F10 (25 mg/ml) and PMA
(50 ng/ml). Where indicated, they were preincubated with inhibitors at 37u
for 30 min before addition of 3F10 or PMA. Aggregation was scored after
2 h using semiquantitative aggregation assay. Effect of metabolic inhibitors
which modulated the 3F10-induced aggregation of thymocytes observed
semiquantitatively was also estimated using quantitative aggregation assay
as described in Materials and Methods. Values are mean from four different
experiments (semiquantitative method) or meantSD from three indepen-
dent experiments (quantitative method). * P<0.001 compared to the
3F10-induced aggregation. Spontaneous aggregation in medium alone was
9.80t2.41. For studies of the divalent cation dependence, the cells were
washed and resuspended in Mg2+ Ca2+ free HBSS medium and various
concentrations of Mg2+ and Ca2+ were added as denoted in the table.
NT=non tested.
Medium
WT1
WT3
1A29
3F10
WT1 + 3F10
WT3 + 3F10
1A29 + 3F10
(a)
50403020100
% aggregation
*
*
Medium
WT1
WT3
1A29
3F10
WT1 + 3F10
WT3 + 3F10
1A29 + 3F10
(b)
50403020100 90807060 100
% bound thymocytes
*
*
Figure 6. (a) Effect of WT1 (anti-CD11a), WT3 and 1A29 (anti-
ICAM-1) mAb on homotypic aggregation of thymocytes triggered by
3F10. Cells were preincubated with these mAbs (10 mg/ml) for 30 min
at 4u before addition of 3F10 mAb. Aggregation was measured
quantitatively as described in Materials and Methods after 2 hr of
incubation. Values are mean tSD from three different experiments.
*P<0.001 compared to the 3F10-induced thymocyte aggregation. (b)
Effect of WT1 (anti-CD11a), WT3 (anti-CD18) and 1A29 (anti-ICAM-
1) mAb on thymocyte binding to R-TNC.1 cells. Thymocyte binding
was determined, as previously described after 45 min of cell culture at
37u. The antibody-mediated modulation of cell binding was tested by
preincubating cells with mAb for 30 min at 4u. Values are mean tSD
from three different experiments. *P<0.01 compared to medium; 2
P<0.001 compared to 3F10.
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cells transfected with rat Crry by flow cytometry. We
demonstrated that 3F10 and 5I2 mAb react with the identical
molecules from thymocyte lysate and show the same reactivity
with rat Crry transfected CHO cells. Therefore, the 3F10
antigen has been identified as the rat Crry/p65 molecule.
However, these mAb show different epitope specificity
(N. Okada, unpublished data).
We have shown that 3F10 mAb induces homotypic
adhesion of rat thymocytes. 3F10-induced aggregation of these
cells is dependent on the active cell metabolism, intact
cytoskeleton and Mg2+. Such dependence is characteristic
for the integrin-mediated adhesion.22 The phenomenon was
further confirmed by mAb blocking studies. We demonstrated
that aggregation of thymocytes was completely blocked by
anti-LFA-1 (anti-CD11a and anti-CD18) mAbs and was only
partly inhibited by anti-ICAM-1 (CD54) mAb suggesting the
involvement of LFA-1-dependent, ICAM-1-dependent and
ICAM-1-independent adhesion pathways. Other ligands for
LFA-1 in this model might be ICAM-2 or ICAM-3. However,
the hypothesis has not been tested, because mAb to these
molecules have not been available in the rat. We also have
demonstrated that the engagement of Crry/p65 by 3F10 mAb
stimulates heterotypic binding of thymocytes to cortical TEC
line (R-TNC.1). The process was LFA-1 dependent but ICAM-
1 independent. The aggregation process presented here is not
specific only for 3F10 mAb, since engagement of a number of
surface molecules on lymphocytes with ligands or mAb (CD2,
CD3–TCR, CD14, CD15, CD16, CD11a, CD18, CD19,
surface immunoglobulin, CD39, CD40, CD43, CD44, MHC
class II, CD99, CD81), generate proadhesive signals that
activate LFA-1 molecules (‘inside-out’ signalling pathway),
resulting in homotypic aggregation of lymphocytes.23–25 It has
been suggested that these intracellular signals enhance the
affinity or avidity of LFA-1 either by conformational changes
or multimerization at the cell surface.22 Likewise, engagement
of the 3F10 antigen can increase LFA-1-mediated adhesiveness
through an ‘inside-out’ signalling pathway.
In further experiments, we tried to define potential
intracellular signalling routes involved in thymocyte aggrega-
tion evoked by 3F10. To date, an exact understanding of the
molecular steps that mediate activation of LFA-1 has remained
elusive. In this context, PKC can serve as the second messenger
for several of known stimuli. However, the use of different
inhibitors suggests that more than one signalling pathways may
play a role in activation of LFA-1 through the inside-out
signalling and that both PK and PP activities have been
implicated in the process.26,27 We showed that activation of
PKC and/or A/G, PP1 and/or PP2A and tyrosine kinases is an
important event for the 3F10-induced adhesion of thymocytes.
Bisindolylmaleimide had no apparent effect, suggesting that
3F10 either did not activate PKC or signals generated upon
binding of 3F10 mAb could act through PKC isoenzymes
insensitive to this inhibitor. In contrast, adhesion evoked by
PMA was suppressed by the inhibitor indicating that 3F10 and
Figure 7. 3F10 mAb enhances proliferation of thymocytes stimulated by ConA. Thymocytes (1r106/ml) were incubated with
0.625 mg/ml Con A alone or with the addition of indicated concentrations of soluble 3F10 (circles) or IrmAb (triangles). The cells were
cultivated for 3 days and [3H]thymidine incorporation was measured as described in Materials and Methods. Values are given as mean
t SD of triplicates of one representative experiment (out of three ones with similar results). *P<0.001 compared to proliferation of
thymocytes in the presence either Con A or IrmAb.
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PMA could use distinct activation mechanisms. The fact that
3F10 exerts an additive effect with PMA in inducing homotypic
adhesion of thymocytes is in agreement with this assumption.
Similarly, Pavlovic´ et al.28 have shown that NG2B12, a mAb
directed to rat CD18, triggers an LFA-1 dependent thymocyte
homotypic adhesion that utilizes distinct intracellular signal-
ling routes in comparison to PMA. Similar results were
reported by Petruzzelli et al.29 using a model of homotypic
aggregation of a B lymphoblastoid cell line (JY). They found
that aggregation of JY cells stimulated by PMA is inhibited by
staurosporine, whereas clustering of these cells induced by anti-
CD18 mAb is staurosporine insensitive. In contrast, aggrega-
tion by both stimuli was completely blocked by pretreatment of
the cells with inhibitors of protein tyrosine kinase (PTK)
(genistein) and PP (okadaic acid). In our experiments, okadaic
acid had inhibitory effect on both PMA-and 3F10-induced
aggregation of thymocytes. Kansas et al.30 have demonstrated
that the LFA-1/ICAM-1-dependent homotypic adhesion of
human B-cell lines induced by mAb reactive with CD19, CD20,
CD39, CD40, CD43, and HLA-DR initiated signal transduc-
tion pathways that involves PTK, but not PKC. In contrast,
Todd et al.25 have shown that the anti-CD81-induced
aggregation of thymocytes that is LFA-1 dependent, was
inhibited by PKC, but not PTK inhibitors. All these reports,
including results obtained in this study, suggest that activation
of LFA-1 is mediated by different activation mechanisms
depending on both engaged cell surface molecules and cell
types.
We have also demonstrated that 3F10 mAb stimulates
proliferation of thymocytes induced by suboptimal Con A
concentrations, indicating that the rat Crry/p65 is involved in
activation of thymocytes. The described functions of the
antigen have not been published either for the mouse Crry/p65
or for its functional homologues in humans.
In conclusion, in the present work we demonstrated that
3F10 mAb, specific for the rat homologue of mouse Crry/p65,
stimulate homotypic adhesion and activation of thymocytes
and binding of thymocytes to TEC. These results suggest that
3F10-derived signals may regulate the thymocyte/TEC adhe-
siveness through activation of LFA-1. In the context of
thymocyte development, the regulation of cell adhesiveness is
of crucial importance. Up to now, a large number of receptor/
ligand interactions have been described in the thymus.4 In
addition, many different signals lead to the activation of LFA-
1.23–25 We demonstrated for the first time that engagement of
the Crry/p65 molecule enhances cell adhesiveness and activa-
tion of thymocytes through LFA-1 and that the phenomenon
may be relevant for selection processes of T cells in the thymus.
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